Evolving liver disease insights from NAFLD to MASLD

Area of Science:

• Hepatology
• Metabolic Disorders
• Liver Disease Research

Background:

• Non-alcoholic fatty liver disease (NAFLD) is a prevalent condition.
• NAFLD is increasingly recognized as a manifestation of metabolic dysfunction.
• The nomenclature requires updating to reflect the underlying pathophysiology.

Purpose of the Study:

• To introduce and justify the renaming of NAFLD to metabolic dysfunction-associated steatotic liver disease (MASLD).
• To emphasize the critical role of metabolic dysfunction in the pathogenesis of steatotic liver disease.
• To advocate for a paradigm shift towards personalized and comprehensive treatment strategies.

Main Methods:

• Review of current literature on NAFLD and metabolic syndrome.
• Analysis of the etiological factors contributing to steatotic liver disease.
• Comparative analysis of existing and proposed nomenclature.

Main Results:

• The term MASLD accurately reflects the metabolic underpinnings of the disease.
• The renaming facilitates a clearer understanding of disease mechanisms.
• It supports the development of targeted therapeutic interventions.

Conclusions:

• The transition from NAFLD to MASLD is crucial for advancing clinical practice and research.
• MASLD emphasizes the need for integrated management of metabolic and liver health.
• This rebranding paves the way for innovative, personalized approaches to steatotic liver disease care.